Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Vipidia

- PMLiVE

Novartis’ blood cancer therapy Kymriah recommended by NICE for routine NHS use

In England, ALL is responsible for around 300 new diagnoses every year in people aged 25 years and under

- PMLiVE

Takeda’s Takhzyro granted MHRA approval for younger hereditary angioedema patients

The rare genetic disorder is estimated to affect one in every 50,000 people

- PMLiVE

Novartis gains rights to Arvinas’ prostate cancer therapy in deal worth over $1bn

The transaction also includes the sale of Arvinas’ preclinical AR-V7 programme

- PMLiVE

Gilead’s Veklury receives NICE recommendation to treat COVID-19 in vulnerable adults and children

Veklury is now the first antiviral recommended by the agency to treat eligible children

- PMLiVE

Novartis shares positive real-world data for Leqvio in atherosclerotic CVD

LDL-C is a causal risk factor for ASCVD and increases the risk of heart disease and stroke

- PMLiVE

Gilead and NHS England extend collaboration to eliminate hepatitis C by 2025

The blood-borne disease is estimated to affect around 62,600 people in England

- PMLiVE

Gilead gains rights to Xilio’s early-stage solid tumour candidate in deal worth up to $647.5m

XTX301 is currently being evaluated in a phase 1 trial in patients with advanced solid tumours

- PMLiVE

Novartis’ Fabhalta recommended by CHMP to treat rare blood disorder PNH

Paroxysmal nocturnal haemoglobinuria affects approximately ten to 20 people per million worldwide

- PMLiVE

Takeda’s HyQvia receives MHRA approval for rare neurological disorder CIDP

The therapy offers patients with CIDP a typical dosing interval of four weeks

- PMLiVE

Takeda’s Iclusig combination granted FDA accelerated approval for rare form of leukaemia

The drug is now the first targeted therapy approved as a frontline treatment for Ph-positive ALL

- PMLiVE

Gilead shares positive real-world data for COVID-19 treatment Veklury in hospitalised patients

Results were presented at the Conference on Retroviruses and Opportunistic Infections

- PMLiVE

Gilead and Merus announce oncology partnership worth over $1.5bn

The companies will aim to discover dual tumour-associated antigens targeting trispecific antibodies

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links